Navigation Links
Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
Date:8/8/2014

SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference in New York next week.  The presentation is scheduled for Tuesday, August 12 at 12:45pm EDT.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's first drug product, Omidria (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. Omeros is completing preparations for an early fall 2014 U.S. product launch. Omidria is currently under review for marketing approval by the European Medicines Agency. Omeros' six clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also
'/>"/>

SOURCE Omeros Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 2015 According to a new market research ... Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, ... by MarketsandMarkets, the Medical Lifting Sling Market is poised to reach ... at a CAGR of 11.4 % from 2015 to 2020. ... rket data T ables and 65 ...
(Date:8/27/2015)... Women Grow , the fastest-growing professional networking organization for women ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... sessions. CWCBExpo in LA will take place September 16-18, 2015 ... in Los Angeles, CA , and is ... marijuana industry. The Women Grow tracks at ...
(Date:8/27/2015)... Aug. 27, 2015  A mere one in seven ... Allen Hamilton . A new white paper ... are impeding and disrupting manufacturers, success. The ... Improve Value In Product Development Processes provides insight ... and how it affects the product development process resulting ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... 2011 PharmAthene, Inc. (NYSE Amex: PIP ... a U.S. Phase I clinical trial of its fully ... prevention and treatment of inhalational anthrax. The ... to evaluate single escalating doses of 1, 5, or ...
... April 13, 2011 Two new studies published in ... Related Diseases, a peer-reviewed journal, add to the ... LAP-BAND® Adjustable Gastric Banding System, made by Allergan, Inc. ... effective weight-loss procedure. One study concluded that laparoscopic adjustable ...
Cached Medicine Technology:PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 2PharmAthene Completes Dosing in Valortim® Phase I Clinical Trial 3New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 2New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 3New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 4New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 5New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 6New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 7New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 8New Clinical Studies Reinforce the LAP-BAND® System is a Safe and Effective Weight-Loss Treatment for Obese Adults with Obesity-Related Comorbid Conditions 9
(Date:8/29/2015)... , ... August 29, 2015 , ... ... angina, chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk ... angina, previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) ...
(Date:8/28/2015)... ... ... Rio Salado College joined nine educational institutions in Washington D.C., ... EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator funded by the ... Incubator hosted by EDUCAUSE and NGLC, which is designed to bring leadership teams ...
(Date:8/28/2015)... New Port Richey, FL (PRWEB) , ... August 28, 2015 , ... ... that while many potential workers are qualified for the position they are applying for, ... work. Because of this, many employers are considering altering drug testing policies in order ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Understanding the FDA’s Position and Best Practices for Compliance, **Presented by FDAnews ... This workshop, chaired by internationally renowned expert Fubin Wu, has been specifically ...
(Date:8/28/2015)... ... August 28, 2015 , ... Loved ones of a ... struggling with chemical dependency, may be able to find some hope in the ... treatment center for addiction located in Western Michigan. Focusing on several different aspects ...
Breaking Medicine News(10 mins):Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 2Health News:Best Drug Rehabilitation Releases New Video Outlining Patients' Personal Recovery Stories 3
... News) -- Progressive scar damage to transplanted kidneys may be ... says a new study. The research included 797 patients ... followed for at least five years. One year after ... signs of progressive scar damage on their new kidney. After ...
... researchers have developed an educational booklet that can help patients ... out of every 16 Americans will be diagnosed with colon ... Most patients survive colon cancer if the cancer ... that can identify and remove polyps from the entire colon. ...
... Maryland, April 12, 2011 Neuralstem, Inc. (NYSE Amex: ... of the Phase I safety trial of Neuralstem,s human ... (ALS or Lou Gehrig,s disease), and unpaid Neuralstem consultant, ... Dr. Feldman reported yesterday at the American Academy of ...
... PARIS, Texas April 12, 2011 Recruitment for ... in the U.S. is now under way in Lamar ... Center, along the Texas-Oklahoma border. The multicenter study ... age 21 to determine how various factors, including environmental ...
... sentinel node (SN) procedure in breast cancer is based on ... tissue drains is clean, the remaining lymph nodes in the ... This was developed to limit surgical overtreatment and reduce morbidities ... in the initial years of the SN procedure, surgeries actually ...
... multiple sclerosis (MS) worry how quickly the disease will ... in a commonly performed diagnostic test, Mayo Clinic researchers ... of disability and counsel them to help ease anxiety. ... of Neurology meeting in Honolulu, Hawaii. Progressive MS ...
Cached Medicine News:Health News:New educational booklet helps patients prepare for a colonoscopy 2Health News:New educational booklet helps patients prepare for a colonoscopy 3Health News:PI presents safety results in Neuralstem ALS Stem Cell Trial 2Health News:PI presents safety results in Neuralstem ALS Stem Cell Trial 3Health News:UT Southwestern pediatricians launch landmark children's health study 2Health News:UT Southwestern pediatricians launch landmark children's health study 3Health News:Mayo Clinic finds tool to predict disability timeline for progressive MS patients 2
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve....
Large deep curve....
Medicine Products: